Varma Mutual Pension Insurance Co Sells 2,800 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Varma Mutual Pension Insurance Co cut its stake in Regeneron by 14.1%, selling 2,800 shares and leaving it with 17,088 shares valued at about $13.19 million.
• Regeneron beat quarterly expectations with EPS of $9.47 (vs. $8.91 expected) and revenue of $3.61 billion, and announced a quarterly dividend of $0.94 (0.5% yield).
• Analysts maintain a consensus rating of Moderate Buy with an average price target of $826.59, while individual targets cited in the article range roughly from $762 to $875.

Varma Mutual Pension Insurance Co cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,088 shares of the biopharmaceutical company's stock after selling 2,800 shares during the period. Varma Mutual Pension Insurance Co's holdings in Regeneron Pharmaceuticals were worth $13,190,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 18.9% during the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company's stock valued at $2,558,804,000 after acquiring an additional 724,562 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 528.7% in the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company's stock worth $405,596,000 after buying an additional 606,612 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company's stock worth $834,675,000 after buying an additional 408,649 shares during the last quarter. Caisse de depot et placement du Quebec boosted its holdings in shares of Regeneron Pharmaceuticals by 115.4% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company's stock worth $260,051,000 after buying an additional 247,780 shares during the last quarter. Finally, Man Group plc boosted its holdings in shares of Regeneron Pharmaceuticals by 257.6% in the 3rd quarter. Man Group plc now owns 271,707 shares of the biopharmaceutical company's stock worth $152,773,000 after buying an additional 195,724 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the business's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 3,874 shares of company stock worth $3,013,262. Company insiders own 6.97% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Evercore boosted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a report on Thursday, January 22nd. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating on the stock in a report on Wednesday, April 8th. Piper Sandler assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They issued an "overweight" rating and a $875.00 price target on the stock. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an "equal weight" rating in a report on Friday, April 10th. Finally, Royal Bank Of Canada cut their price target on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a "sector perform" rating on the stock in a report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $826.59.

Regeneron Pharmaceuticals Trading Up 1.1%

Shares of Regeneron Pharmaceuticals stock opened at $709.21 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The stock's 50-day simple moving average is $756.81 and its 200 day simple moving average is $737.56. The stock has a market capitalization of $74.98 billion, a P/E ratio of 17.28, a P/E/G ratio of 1.60 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analysts' expectations of $3.48 billion. During the same period in the previous year, the business posted $8.22 EPS. The firm's quarterly revenue was up 19.0% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.05 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.